Approval · Notice of Compliance 38316 · 2026
FERRIPROX: Notice of Compliance 38316
Issued September 17, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 38316
- Date
- September 17, 2026
- Company
- Chiesi Canada Corp.Woodbridge, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph with new safety and efficacy information
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| FERRIPROX | Not yet assigned | — |
| FERRIPROX MR | Not yet assigned | — |
Medicinal ingredients
- DEFERIPRONE 500 MG per TAB
- DEFERIPRONE 1,000 MG per TAB
- DEFERIPRONE 100 MG per ML